TIL
Advanced Liver Cancers
Shanghai Juncell TherapeuticsCell therapyPhase 1Active
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 35/ 100
- Competitive Position
- 95/ 100
Competitive context
111 Active assets in the Advanced Liver Cancers cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bxcl501 Uppsala University Hospital | Phase 4 | BBB |
Inno-206 Shanghai Zhongshan Hospital | Phase 4 | BB |
Eloxatin Sun Yat-sen University | Phase 3 | BB |
Hepatitis B Virus Vaccine Eunice Dube | Phase 4 | BB |
Tranexamic Acid Konkuk University Medical Center | Phase 4 | BB |
View all 50 →
Same molecule, other indications
TIL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →